- Home
- PCVX vs LEGN Comparison
PCVX vs LEGN Comparison
Compare PCVX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCVX | LEGN |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.9B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PCVX | LEGN |
|---|---|---|
| Price | $47.35 | $23.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $105.00 | $69.33 |
| AVG Volume (30 Days) | 1.1M | ★ 2.1M |
| Earning Date | 02-24-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $909,045,000.00 |
| Revenue This Year | N/A | $68.20 |
| Revenue Next Year | N/A | $47.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 74.75 |
| 52 Week Low | $27.66 | $20.21 |
| 52 Week High | $93.77 | $45.30 |
Technical Indicators
Market Signals| Indicator | PCVX | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.21 | 51.91 |
| Support Level | $44.57 | $20.21 |
| Resistance Level | $48.93 | $24.12 |
| Average True Range (ATR) | 2.27 | 1.18 |
| MACD | 0.15 | 0.36 |
| Stochastic Oscillator | 64.32 | 88.23 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.